TheStreet's Adam Feuerstein Tweets '$PTCT sets a very low bar for NICE reimbursement, helpful to $SRPT $BMRN if they can get their DMD drugs approved.'
Get News First. Profit Faster
With Benzinga Professional get unlimited access to ALL content! PLUS:
- REALTIME NEWSFEED
- REALTIME AUDIO NEWS
- FULL CALENDAR SUITE
- CHAT WITH OUR NEWS DESK
RECENT PRO ALERTS
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.